Antibody-targeted chemotherapy of acute myeloid leukemia using gemtuzumab ozogamicin (Mylotarg)

Blood Cells, Molecules, and Diseases

Volumn 31, Issue 1, 2003, Pages 7-10

  Sievers, Eric L ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ZYMOGENETICS INC   (United States)

Author keywords

Acute myelogenous leukemia; Gemtuzumab ozogamicin; Immunoconjugate; Monoclonal antibody; Mylotarg

Indexed keywords

AMINOTRANSFERASE; GEMTUZUMAB OZOGAMICIN; LIVER ENZYME; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ARTICLE; ASCITES; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CEREBELLUM DISEASE; CHILL; CLINICAL TRIAL; DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEVER; HEPATOSPLENOMEGALY; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKEMIA CELL; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0038351870     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00117-7     Document Type: Article

References (12)

1. Andrews R.G., Singer J.W., Bernstein I.D. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J. Exp. Med. 169:1989;1721-1731.
2. Scheinberg D.A., Lovett D., Divgi C.R., Graham M.C., Berman E., Pentlow K., et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia specific bone marrow targeting and internalization of radionuclide . J. Clin. Oncol. 9:1991;478-490.
3. Appelbaum F.R., Matthews D.C., Eary J.F., Badger C.C., Kellogg M., Press O.W., et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 54:1992;829-833.
4. van der Jagt R.H., Badger C.C., Appelbaum F.R., Press O.W., Matthews D.C., Eary J.F., et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 52:1992;89-94.
5. Sievers E.L., Appelbaum F.A., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy a phase I study of an anti-CD33 calicheamicin immunoconjugate . Blood. 93:1999;3678-3684.
6. Sievers E.L., Arceci R., Franklin J., Lange B.J., Shannon K., Smith F.O., et al. Preliminary report of an ascending dose study of gemtuzumab ozogamicin (Mylotarg, CMA-676) in pediatric patients with acute myeloid leukemia. Blood. 96:2000;217b.
7. C.M. Zwaan, D. Reinhardt, S. Corbacioglu, E.R. Van Wering, J.P. Bokkerink, W.J. Tissing, Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate use basis, Blood 101 (2003) 3868-3871.
8. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B.L., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 19:2001;3244-3254.
9. Sievers E.L., Larson R.A., Estey E., Stadmauer E.A., Castaigne S., Berger M.S., et al. Low incidence of hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676) relationship to hematopoietic stem cell transplantation (Abstract) . Blood. 96:2000;206b.
10. Giles F.J., Kantarjian H.M., Kornblau S.M., Thomas D.A., Garcia-Manero G., Waddelow T.A., et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 92:2001;406-413.
11. De Angelo D., Schiffer C., Stone R., Amrein P., Fernandez H., Bradstock K., et al. Interim analysis of a phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. Blood. 200:2002;198a.
12. Kell J.W., Burnett A.K., Chopra R., Yin J., Culligan D., Clark R., et al. Mylotarg (gemtuzumab ozogomycin: GO) given simultaneously with intensive induction and/or consolidation therapy for AML is feasible and may improve the response rate. Blood. 100:2002;199a.